BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28237180)

  • 1. Plasma Cytokines Correlated With Disease Characteristics, Progression-Free Survival, and Overall Survival in Testicular Germ-Cell Tumor Patients.
    Svetlovska D; Miskovska V; Cholujova D; Gronesova P; Cingelova S; Chovanec M; Sycova-Mila Z; Obertova J; Palacka P; Rajec J; Kalavska K; Usakova V; Luha J; Ondrus D; Spanik S; Mardiak J; Mego M
    Clin Genitourin Cancer; 2017 Jun; 15(3):411-416.e2. PubMed ID: 28237180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
    Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
    Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of plasma miR-371a-3p in germ cell tumors.
    Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
    J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
    Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
    Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model based on tumor-infiltrating immune cells for predicting the relapse rates of patients with testicular germ cell tumors.
    Wang Y; Ji C; Liu J; Wang Y; Song N; Cao P
    Int Immunopharmacol; 2020 Sep; 86():106710. PubMed ID: 32652500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age as a Predictor of Treatment Outcome in Metastatic Testicular Germ Cell Tumors.
    Terbuch A; Posch F; Bauernhofer T; Pichler M; Peinsith H; Szkandera J; Riedl J; Hutterer GC; Pummer K; Partl R; Kapp KS; Stöger H; Stotz M; Gerger A
    Anticancer Res; 2019 Oct; 39(10):5589-5596. PubMed ID: 31570454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer.
    Blok JM; Groot HJ; Huele EH; de Wit R; Horenblas S; Nuver J; Groenewegen G; Bosch JLHR; Witjes JA; Tromp JM; de Brouwer PJM; van den Berg HA; Vanneste BGL; Smilde TJ; Aarts MJB; Gietema JA; Meijer RP; Schaapveld M
    J Clin Oncol; 2021 Feb; 39(4):319-327. PubMed ID: 33119475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
    J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia.
    Klein B; Haggeney T; Fietz D; Indumathy S; Loveland KL; Hedger M; Kliesch S; Weidner W; Bergmann M; Schuppe HC
    Hum Reprod; 2016 Oct; 31(10):2192-202. PubMed ID: 27609978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.
    Fedyanin M; Tryakin A; Bulanov A; Fainshtein I; Zakharova T; Matveev V; Garin A; Tjulandin S
    Urol Oncol; 2014 Jan; 32(1):32.e27-33. PubMed ID: 23628310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
    Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.
    Shintaku I; Satoh M; Okajima E; Fujimoto H; Kamoto T; Ogawa O; Kawai K; Akaza H; Tsukamoto T; Naito S; Miki T; Arai Y
    Jpn J Clin Oncol; 2008 Apr; 38(4):281-7. PubMed ID: 18321891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
    Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
    J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.